论文信息 - Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 - 字舞流文

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

H. Kantarjian | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | M. L. Paccagnella | E. Vandendries | R. Cassaday | M. Stelljes | A. Laird | Tao Wang | A. Neuhof | K. Nguyen | B. Sleight